{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-002490","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.514320+00:00","generated_at":"2026-06-27T19:19:38.026284+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ironwood expects LINZESS to exceed $1B in 2021 US net sales; raises 2021 adjusted EBITDA guidance to >$230M","bullets":["LINZESS U.S. net sales expected to surpass $1B in 2021, achieving blockbuster status.","2021 guidance updated: LINZESS growth at high end of 6-8%; total revenue high end of $390-410M.","Adjusted EBITDA guidance raised to >$230M (from >$210M) for 2021.","2022 guidance: LINZESS low single-digit growth; total revenue $420-430M; adjusted EBITDA >$250M.","Board authorized $150M share repurchase; $27M repurchased in Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-002490","json":"https://secwatch.observer/filing/0001104659-22-002490.json","markdown":"https://secwatch.observer/filing/0001104659-22-002490.md","text":"https://secwatch.observer/filing/0001104659-22-002490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922002490/0001104659-22-002490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922002490/tm222198d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:19:38.026284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}